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ABSTRACT
Insulin resistance plays a major role in the pathogenesis of type 2 diabetes and is an impor-
tant risk factor for cardiovascular disease. Endothelial dysfunction, characterized by reduced 
bioactivity of nitric oxide and increased activity of the vasoconstrictor and pro-inflammatory 
peptide endothelin-1 (ET-1), is present in insulin-resistant states and is an important factor 
promoting the development of cardiovascular complications in patients with insulin resis-
tance. The aim of the thesis was to explore the mechanisms linking insulin resistance to 
endothelial dysfunction. The hypothesis was that ET-1 via activation of its receptors, ETA and 
ETB, contributes to endothelial dysfunction and reduced insulin sensitivity in subjects with 
type 2 diabetes mellitus and insulin resistance.
Study I
The effect of the blockade of ET receptors on endothelium-dependent vasodilatation was 
studied in 12  individuals with insulin resistance without any history of diabetes or cardio-
vascular disease. Local intra-arterial dual ETA/ETB receptor blockade, but not selective ETA 
blockade, enhanced forearm endothelium-dependent vasodilatation.
Study II
The importance of endogenous ET-1 for the regulation of total body glucose uptake and in-
sulin sensitivity was studied in 7 patients with insulin resistance and coronary artery disease. 
Intravenous dual ETA/ETB receptor blockade, but not selective ETA blockade, enhanced insu-
lin sensitivity in this patient group.
Study III
We studied if ET-1 regulates skeletal muscle glucose uptake in 11 insulin resistant subjects in 
vivo and in cultured human skeletal muscle cells. Intra-arterial dual ETA/ETB receptor block-
ade enhanced basal and insulin-stimulated forearm glucose uptake in insulin resistant sub-
jects. ET-1 directly impaired glucose uptake in skeletal muscle cells via a receptor-dependent 
mechanism. 
Study IV
The effect of exogenous ET-1 on basal forearm glucose uptake was studied in 9 subjects with 
insulin resistance and in cultured human skeletal muscle cells. Intra-arterial ET-1 infusion 
not only induced vascular dysfunction, but also acutely impaired forearm glucose uptake in 
individuals with insulin resistance and in skeletal muscle cells from type 2 diabetic subjects. 
The mechanism seems to be related to signaling downstream of IRS1 Ser636.
Collectively, the obtained data suggest that ET-1 is of pathophysiological importance for the 
development of endothelial dysfunction and contributes to glucometabolic perturbations in 
subjects with insulin resistance. Dual ETA/ETB receptor blockade may be a potential thera-
peutic target in order to improve endothelial function and insulin sensitivity in this patient 
group.
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LIST OF ABBREVIATIONS
ACE Angiotensin converting enzyme
Ach Acetylcholine
AMPK 5’-adenosine monophosphate-activated protein kinase
ATP Adenosine-5’-triphosphate
BMI Body mass index
CG Cardiogreen
CRP C-reactive protein
ECM Extracellular matrix
EDV Endothelium-dependent vasodilatation
EIDV Endothelium-independent vasodilatation
eNOS Endothelial nitric oxide synthase
ERK Extracellular regulated kinase
ET-1 Endothelin-1
FBF Forearm blood flow
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GLUT4 Glucose transporter type 4
Grb2 Growth factor receptor-bound protein 2
GSK Glycogen synthase kinase
HbA1c Glycated hemoglobin
HDL High-density lipoprotein
HOMA Homeostasis model assessment
IRS Insulin receptor substrate
LDL Low-density lipoprotein
MAPK Mitogen-activated protein kinase
MMPs Matrix metalloproteases
NO Nitric oxide
OGTT Oral glucose tolerance test
PAH P-aminohippurate
PDGF Platelet-derived growth factor
PDK Pyruvate dehydrogenase kinase
PI3-K Phosphatidylinositol 3-kinase
PKA Protein kinase A
PKC Protein kinase C
RBF Renal blood flow
ROS Reactive oxygen species
RVR Renal vascular resistance
SBF Splanchnic blood flow
Shc Src-homology-2-containing transforming protein
SNP Sodium nitroprusside
SOS Guanine nucleotide exchange factor Son of Sevenless
SplVR  Splanchnic vascular resistance
TG Triglycerides
TGFβ Transforming growth factor β
VCAM-1 Vascular cell adhesion molecule-1
VEGF Vascular endothelial growth factor
VLDL Very low-density lipoprotein
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INTRODUCTION
General background
Insulin resistance is a pathological condition, which is defined as the reduced responsiveness 
of insulin-sensitive tissues (mainly liver, skeletal muscle and adipose) or a target cell to insulin 
exposure. This results in reduced insulin-stimulated glucose uptake in peripheral tissues, 
the lack of inhibition of hepatic glucose production and, in an effort to maintain glucose 
homeostasis, a compensatory increase in insulin secretion, resulting in hyperinsulinemia.1 
Insulin resistance plays a major role in the pathogenesis of type 2 diabetes, a metabolic 
disorder characterized by chronic hyperglycemia, with disturbances of carbohydrate, fat and 
protein metabolism, resulting from the defects of insulin action.2 Type 2 diabetes comprises 
90% of people with diabetes around the world. It is associated with reduced life expectancy 
and significant morbidity due to specific diabetes related microvascular complications, 
increased macrovascular complications (ischemic heart disease, stroke and peripheral 
vascular disease), and diminished quality of life. Recent estimates indicate there were 246 
million people in the world with diabetes in the year 20073 and this is expected to increase to 
at least 366 million by 2030.4 Insulin resistance is present not only in the majority of patients 
with type 2 diabetes, but also in the early pre-diabetic state of impaired glucose tolerance and 
in individuals with normal glucose tolerance who are the offspring of patients with type 2 
diabetes.5 For this reason, insulin resistance not only plays a major role in the pathogenesis 
of type 2 diabetes, it is also an initial measurable defect predicting the development of 
type 2 diabetes.6 Moreover, insulin resistance is an important risk factor for cardiovascular 
disease,7-9 which is the major cause of death and disability in patients with type 2 diabetes10 
and the leading cause of overall morbidity and mortality in the developed countries.11 
Insulin resistance is also closely associated with other major public health problems, 
including obesity, hypertension and dyslipidemia. A global obesity epidemic is currently 
driving the increased incidence and prevalence of insulin resistance and its cardiovascular 
complications.12 There are several reasons why patients with insulin resistance and type 2 
diabetes are particularly prone to develop coronary events. They include disturbed platelet 
function, reduced fibrinolytic capacity, dyslipidemia and hyperglycemia.13, 14 Interestingly, 
all these conditions may contribute to a state that is usually referred to as “endothelial 
dysfunction”. This term refers to the dysfunctional endothelium with an impaired ability to 
maintain vascular homeostasis. Endothelial dysfunction contributes to the pathogenesis of 
atherosclerosis,15 insulin resistance16 and vascular disease in type 2 diabetes.17 Furthermore, 
it is closely related to clinical events in patients with atherosclerosis, hypertension and type 
2 diabetes.10, 18 Endothelial dysfunction could therefore be one of the possible mechanisms 
leading to the development of atherosclerosis and its clinical complications in patients with 
insulin resistance. The objective of this thesis is to explore the mechanisms linking insulin 
resistance to endothelial dysfunction.
The endothelium and endothelial function
The endothelium, which is a monolayer of endothelial cells, is localized at the interface 
between the vessel wall and circulating blood. The discovery almost three decades ago that 
the endothelium is not an inert semi-permeable barrier that prevents the leakage of excessive 
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plasma fluid through the monolayer but is also able to elicit vasodilatation19 led to a revolution 
in vascular biology. In fact, by producing a large number of biologically active substances, 
the endothelium plays a pivotal role in cardiovascular homeostasis. It participates in the 
regulation of vascular tone, thrombosis and hemostasis, vascular permeability, blood pressure, 
the recruitment and activity of inflammatory cells and cell growth. Endothelial cells are able 
to produce both vasodilator and vasoconstrictor substances. The main endothelium-derived 
relaxing factors are nitric oxide (NO), prostacyclin and endothelium-derived hyperpolarizing 
factor. The main vasoconstricting substances produced by the endothelium are thromboxane 
A2, angiotensin II and endothelin (ET)-1. The release of endothelium-derived vasodilators 
can be induced by several physiological and pharmacological factors, such as acetylcholine, 
serotonin, angiotensin II, alpha adrenergic agonists and increased shear stress. When affecting 
vascular smooth muscle, the very same factors promote vasoconstriction. The vascular 
endothelium thus plays an important role in maintaining the delicate balance of vascular 
tone.
The gaseous molecule NO – the most potent endothelium-derived vasorelaxing substance 
and an important determinant of endothelial function – is generated from the conversion 
of the amino acid L-arginine by endothelial NO synthase (eNOS). Classical cholinergic 
vasodilators (e.g. acetylcholine) activate G-coupled receptors on endothelial cells, which 
results in a rise in intracellular calcium levels. The calcium/calmodulin complex interacts 
with the calmodulin-binding site on eNOS, thereby increasing its enzymatic activity. Another 
pathway leading to eNOS activation is the direct phosphorylation of eNOS at Ser1177 by 
different serine kinases, including Akt, 5’ adenosine monophosphate-activated protein kinase 
(AMPK) and protein kinase A (PKA). The availability of L-arginine and enzymatic cofactors 
(e.g. tetrahydrobiopterin) also plays an important role in the regulation of NO production.20 
Once formed in endothelial cells, NO diffuses freely into adjacent vascular smooth muscle 
cells, where it activates guanylate cyclase which in turn increases guanosine monophosphate 
levels to induce vasodilatation. In addition to its vasorelaxing action, NO can also exhibit other 
vasoprotective properties such as the attenuation of inflammation. This effect is obtained by 
reducing the expression of different adhesion molecules. They include vascular cell adhesion 
molecule-1 (VCAM-1), E-selectin and intercellular adhesion molecule-1 (ICAM-1).21 NO 
also inhibits the production and/or release of several inflammatory cytokines and chemokines, 
such as tumor necrosis factor-α, monocyte chemoattractant protein-1,22  tissue factor,23 
interleukin-6 and interleukin-8.21 As a result, NO attenuates the binding of inflammatory 
cells such as monocytes and macrophages to the vascular wall, as well as platelet adhesion.24 
These effects are attributed to the ability of NO to inhibit actions of the transcription factor 
nuclear factor kappa B.25In addition, NO inhibits vascular smooth muscle cell growth and 
proliferation26, 27 and intimal hyperplasia, which involves both the proliferation and migration 
of vascular smooth muscle cells.28 In the cellular environment, NO may react with reactive 
oxygen species (ROS) to form strong oxidant intermediates such as peroxynitrite (ONOO–) 
via the reaction with superoxide. The inactivation of NO by the enhanced production of 
ROS in the vasculature can significantly reduce NO bioavailability. Under physiological 
conditions, adequate levels of NO are maintained by the efficiency of antioxidant enzymes 
that quench ROS production and thereby limit peroxynitrite formation.29 The bioavailability 
of NO, i.e. the concentrations of free NO available to produce a biological response, is 
therefore dependent on the balance between the production by eNOS and the inactivation of 
NO by oxidative processes.
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In the healthy artery, the balance of vasoactive substances produced by the endothelium 
favors vasorelaxation and anti-thrombotic and anti-inflammatory effects (Fig 1A). In disease, 
there is a shift towards the reduced bioavailability of NO, which in turn results in enhanced 
vascular tone, increased oxidative stress, platelet activation and inflammatory activity (Fig 
1B). This maladapted endothelial phenotype, referred to as “endothelial dysfunction”, is 
present in many cardiovascular and metabolic disorders, such as hypertension,30 coronary 
artery disease,15 dyslipidemia,31 obesity,32 insulin resistance33 and type 2 diabetes.17 Almost 
25 years ago, Ludmer et al. demonstrated that prestenotic and stenotic segments of coronary 
arteries exhibited a paradoxical vasoconstriction in response to the intra-arterial infusion 
of acetylcholine.15 In fact, endothelial dysfunction has been shown to be one the earliest 
manifestations of the atherosclerosis process, where abnormal vasoconstriction can be 
observed at the site of future plaque development.34 It is important to note that the impairment 
of endothelial function involves several other biological processes apart from the reduced 
bioavailability of NO. One of them is the increased production and biological activity of ET-1, 
a peptide with potent vasoconstrictor and pro-inflammatory properties.35 
Endothelin-1 and its role in endothelial dysfunction
ET-1 belongs to the family of endothelins which comprises three vasoactive peptides, ET-1, 
ET-2 and ET-3. ET-1, described by Yanagisawa et al. in 1988,36 is regarded as the most important 
endothelin isoform for the cardiovascular system.37 ET-1 is synthesized in endothelial 
cells from its inactive precursors prepro ET-1 and big ET-1, processed by a subgroup of 
Figure 1. Schematic figure of the arterial wall under healthy conditions (left) and in endothelial 
dysfunction (right). In healthy arteries, the production of ET-1 is small and the bioavailability 
of nitric oxide (NO) is preserved, which favors vasorelaxation. In endothelial dysfunction, 
the expression of ET-1 in smooth muscle cells is increased. The expression of ETB receptors 
on smooth muscle cells is increased, leading to increased vasoconstriction. ET-1 may reduce 
endothelial NO synthase (eNOS) expression, which results in reduced NO production. ET-1 
may mediate the formation of superoxide (O2–), thereby reducing the biological activity 
of NO by forming peroxynitrite (ONOO–). ET-1 stimulates the production of extracellular 
matrix (ECM) and matrix metalloproteases (MMPs), resulting in vascular remodeling.
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membrane-bound zinc metalloproteases, the endothelin-converting enzymes (ECEs), into the 
active ET-1. ET-1 is also produced in other cell types such as vascular smooth muscle cells, 
cardiac myocytes,38 macrophages39 and leukocytes.40 ET-1 acts mainly in a paracrine manner, 
exerting its effects via the activation of two G-protein coupled receptors, namely the ETA and 
ETB receptor subtypes, which are located on vascular smooth muscle cells (both ETA and 
ETB) and endothelial cells (ETB only). The stimulation of both receptor subtypes on vascular 
smooth muscle cells leads to vasoconstriction via intracellular calcium release, while the 
stimulation of ETB receptors on endothelial cells leads to vasodilatation due to the release of 
NO and prostacyclin (Fig. 1A). ET-1 stimulates vascular smooth muscle cells proliferation,41 
the migration,42 contraction43 and expression of pro-atherogenic growth factors like platelet-
derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and transforming 
growth factor (TGF)β.44, 45 In vascular smooth muscle cells and fibroblasts, the expression 
of extracellular matrix and matrix metalloproteinases is stimulated by ET-1 via the ETA-
mediated pathway, which may lead to the promotion of tissue remodeling.46, 47 
Many pathological conditions, such as type 2 diabetes,48 obesity,49 essential hypertension50 
and coronary artery disease,51 are associated with elevated plasma levels of ET-1. A complex 
interaction between ET-1 and NO appears to exist in the vascular wall. Endogenous NO is 
known to down-regulate ET-1 secretion.52 On the other hand, ET-1 impairs endothelium-
dependent vasodilatation induced by NO.53 Accordingly, ET receptor blockade improves 
endothelium-dependent vasodilatation in patients with atherosclerosis54 and hypertension.55 
There could be several reasons for these effects. First, it has been demonstrated that the dual ET 
receptor antagonist bosentan increases the expression of eNOS.56 Furthermore, eNOS activity 
is stimulated by dual ET receptor blockade.57 Second, increased ROS production due to the 
excessive stimulation of both ETA and ETB receptors could result in increased NO degradation 
with the formation of peroxynitrite. Moreover, ET-1 induces the up-regulated expression of 
caveolin-1 − the major coat protein of caveolae, which appears to be a key negative regulatory 
protein for eNOS activity58 − leading to the inhibition of eNOS activity.59, 60 
It is often assumed that most of the negative effects of ET-1 are mediated via the stimulation 
of the ETA receptor. In fact, in physiological conditions, vasoconstriction is mainly mediated 
by the ETA receptor, which is partly counteracted by the release of NO mediated by ETB 
receptors located on endothelial cells. Selective ETA receptor antagonism has been reported 
to have positive effects on vascular function. The ETA receptor antagonist BQ123 evokes 
an increase in forearm blood flow in healthy men.61 Conversely, in another report, BQ123 
increased forearm blood flow only in hypertensive patients but not in normotensive controls.62 
Furthermore, hypertensive patients with obesity respond to ETA receptor antagonism with a 
higher increase in blood flow, compared with lean hypertensive patients.63 Selective ETA 
receptor blockade was reported to improve nutritive skin capillary circulation in patients with 
type 2 diabetes and microangiopathy.64 At the same time, ETB receptor antagonism (alone or 
in combination with ETA receptor antagonism) was shown to induce local vasoconstriction 
in young healthy subjects.65 Possible explanations for this effect are that the ETB receptor 
antagonist blocks the vasodilator ETB receptor on endothelial cells and that ETB receptors 
are of importance for the clearance of ET-1.66 It has therefore been speculated that the 
blockade of endothelial ETB receptors may be detrimental for vascular function.
57 On the 
other hand, there are indications of an up-regulation of vasoconstricting ETB receptors on 
vascular smooth muscle cells that may contribute to vascular dysfunction in pathological 
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conditions. There is evidence of the increased expression of ETB receptors in atherosclerotic 
human arteries,67 as well as in a mouse model overexpressing ET-1.68 Accordingly, dual ETA/
ETB receptor blockade increases endothelial NO synthase activity more than selective ETA 
receptor blockade in hypercholesterolemic pigs69 and dual ETA/ETB receptor blockade results 
in more pronounced vasodilatation than selective ETA receptor blockade in patients with 
atherosclerosis.70 It can therefore be speculated that dual ETA/ETB receptor antagonism is 
beneficial in vascular dysfunction associated with atherosclerosis. The effect of dual ETA/
ETB receptor blockade on vascular function in insulin resistance and type 2 diabetes remains 
to be clarified.
Insulin actions and signaling in vascular endothelium in health and disease
Insulin is a powerful anabolic hormone whose primary role is to promote fuel storage (by 
increasing glycogen synthesis in the liver and muscle, augmenting triglyceride synthesis and 
deposition in adipose tissue and promoting protein synthesis and inhibiting proteolysis) and 
enhance glucose oxidation, providing an important energy source in the form of adenosine-
5’-triphosphate (ATP). To exert these actions, insulin needs to cross the endothelial barrier 
to reach its target receptor in insulin-sensitive tissues. The exact mechanism has not yet been 
fully elucidated, but the insulin molecule is thought to be internalized by vascular endothelial 
cells via a receptor-mediated process.71 Insulin receptors are expressed at the cell surface 
plasma membrane. The insulin receptor consists of four subunits, two extracellular insulin-
binding α-peptides linked with two transmembrane β-peptides. On the intracellular side of the 
β-subunits, there is a tyrosine kinase domain. When insulin binds to the receptor, conformational 
change results in the activation of the β-subunits through autophosphorylation on tyrosine 
residues, providing docking sites for the binding of down-stream signaling molecules. There 
are two major branches of the complex insulin signal transduction network.
The metabolic branch stimulates glucose transporter type 4I)  (GLUT4) translocation to 
the cell membrane and thereby regulates glucose uptake72 in adipocytes and myocytes. 
This action is mediated by the activation of the insulin receptor substrate (IRS)-1, which 
results in the downstream activation of phosphatidylinositol 3-kinase (PI3-K) and the 
subsequent phosphorylation of the serine/threonine kinase Akt.73, 74 The effect of Akt on 
glucose uptake has been linked to the phosphorylation of its substrate AS16075 (also called 
TBC1D4), which regulates Rab proteins involved in GLUT4 vesicle translocation.76 Fur-
thermore, Akt phosphorylates glycogen synthase kinase-3 (GSK-3) resulting in glycogen 
synthesis.77 Additional Akt-independent pathways have been implicated in the mediation 
of insulin-stimulated glucose transport, involving the phosphoinositide-dependent protein 
kinase-1 (PDK)-1 and protein kinase C (PKC) isoforms ζ/λ (Fig. 2).78 
TheII)  mitogen-activated protein kinase (MAPK)-dependent pathway is involved in insu-
lin signaling related to gene expression, mitogenesis, cell growth and differentiation.79 
Interestingly, this pathway is also implicated in the insulin-stimulated secretion of ET-1 
(Fig. 2).80
The insulin-mediated stimulation of the PI3-K pathway in the vascular endothelium, which 
exhibits striking parallels with the metabolic insulin signaling pathway in muscle and adi-
pose tissue, results in the phosphorylation of serine-threonine kinases including Akt and the 
direct phosphorylation of eNOS (Fig. 2).81, 82 This leads to the stimulation of NO production, 
         Endothelin-1 and insulin resistance
13
vasodilatation, increased capillary recruitment and elevated total blood flow.83 These vascular 
actions augment the delivery of insulin and glucose to skeletal muscle, thereby enhancing 
glucose uptake and utilization. It has been proposed that as much as 25% of the stimula-
tory effect of insulin on muscle glucose uptake is related to its hemodynamic actions.84 The 
specificity of this NO-dependent mechanism has been confirmed using a specific inhibitor of 
eNOS (NG-monomethyl-L-arginine) which substantially reduced insulin-mediated vasodila-
tation.85 The same effect could be obtained following the inhibition of the essential co-factor 
of NO synthesis, tetrahydrobiopterin.86 At the same time, insulin-stimulated NO production 
could be antagonized by inhibitors of PI3-kinase or Akt.87, 88 In addition to this vasodilating 
effect, insulin also exerts vasoconstricting effects by stimulating the sympathetic nervous 
system89 and the release of ET-1. 
The interactions between insulin and vascular function are complex and may differ between 
healthy and insulin-resistant states. In obese subjects with insulin resistance, as compared to 
insulin-sensitive lean subjects, impaired insulin diffusion across the vascular endothelium 
was described, representing a potential rate-limiting step in peripheral insulin action.90 
The vasodilatory effect of insulin is blunted due to alterations in insulin signaling in obese 
Figure 2. Schematic view of the insulin signaling pathway. The phosphatidylinositol 
3-kinase (PI3-K) branch regulates glucose transporter type 4 (GLUT4) translocation and 
nitric oxide (NO) production via phosphorylation of the endothelial nitric oxide synthase 
(eNOS). It also regulates glycogen synthesis via phosphorylation of the glycogen synthase 
kinase 3 (GSK3). The mitogen-activated protein kinase (MAPK) branch, which include 
Src-homology-2-containing transforming protein (Shc), growth factor receptor-bound 
protein 2 (Grb2) and guanine nucleotide exchange factor (SOS), regulates gene expression, 
cell growth, mitogenesis and the production of  endothelin-1 (ET-1).
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subjects and patients with type 2 diabetes,91 as well as in animal models of insulin resistance.92 
Furthermore, in insulin-resistant states of obesity and type 2 diabetes, an impaired response 
to different endothelium-dependent vasodilators (acetylcholine, metacholine and bradykinin) 
has also been reported.93 On a molecular level, metabolic insulin resistance results from 
impaired PI3-K-dependent signaling − the same pathway that is involved in the regulation 
of NO production in the endothelium − thereby leading to the reduced bioavailability of NO. 
Coexisting hyperinsulinemia results in the activation of genes involved in inflammation94 and 
excessively activates the MAPK pathway in a pro-atherogenic manner: IRS1 interacts with 
Src-homology-2-containing protein (Shc), leading to the activation of extracellular regulated 
kinase (ERK), which catalyses the phosphorylation of transcriptional factors that promote 
cell growth, cell proliferation, cell differentiation and ET-1 production (Fig. 2).81, 82, 95
Other factors aggravating endothelial dysfunction in insulin resistance
Insulin resistance most often precedes impaired glucose tolerance and hyperglycemia.96 So, 
despite the fact that hyperglycemia plays a major role in the development of endothelial 
dysfunction in type 2 diabetes via the activation of different signaling pathways leading 
to increased oxidative stress,13 it is unlikely that this is the case at the pre-diabetic stage. 
Abdominal obesity accompanied by dyslipidemia and low-grade inflammation is a common 
feature in insulin resistance, which could also promote the development of endothelial 
dysfunction. Increased levels of circulating free fatty acids and triglycerides induce a reduction 
in vascular reactivity, presumably via both endothelium-dependent and endothelium-
independent mechanisms.97 In insulin-resistant subjects, serum levels of free fatty acids are 
generally increased, resulting in the excessive production of superoxide and the reduction of 
eNOS activity.98 The increased generation of ROS could additionally aggravate endothelial 
function in insulin-resistant states due to the reduction of NO bioavailability.99 In recent 
studies, high-density lipoprotein (HDL) cholesterol and adiponectin were shown to stimulate 
the production of NO from vascular endothelium by a PI3-K-dependent mechanism.100, 
101 Reduced levels of HDL cholesterol and adiponectin may therefore contribute to the 
decrease in NO bioavailability. Additionally, increases in the levels of very-low-density 
lipoprotein (VLDL) particles are correlated to endothelial dysfunction.102 Many studies have 
demonstrated that insulin by itself is able to promote atherogenesis via several mechanisms, 
such as the stimulation of de novo lipogenesis, the enhancement of VLDL synthesis, increased 
cholesterol transport in arteriolar smooth muscle cells, the augmentation of collagen synthesis 
and the stimulation of the proliferation of arteriolar smooth muscle cells.103 The production of 
proinflammatory cytokines, such as tumor necrosis factor α (TNFα), is increased in obesity. 
TNFα may selectively inhibit the PI3-kinase signaling pathway and induce endothelial 
dysfunction by altering the balance between NO and ET-1.104
ET-1 and the regulation of glucose uptake
Recent studies suggest that ET-1 may be involved in the regulation of glucose uptake by di-
rectly inhibiting insulin-mediated glucose uptake via a receptor-dependent mechanism. Cell 
culture studies demonstrate that ET-1 impairs insulin-stimulated glucose transporter GLUT4 
translocation in adipocytes105, 106 and reduces PI3-kinase activity via IRS2 serine and tyrosine 
phosphorylation in isolated vascular smooth muscle cells.107 There is also evidence that ET-1 
impairs GLUT4 trafficking via PI3-kinase independent membrane-based signal transduc-
tion Cbl associated protein (CAP)/Cbl pathway.106 In isolated rat soleus muscle strips, ET-1 
pretreatment for one hour leads to a reduction in insulin-stimulated glucose transport. In 
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the same animal model, chronic ET-1 administration in vivo leads to whole-body insulin 
resistance, with decreased skeletal muscle glucose transport and impaired insulin signaling 
(reduction in the expression of IRS1 protein and IRS1-associated p110alpha phosphoinosit-
ide 3-kinase, as well as Akt activation).108 In humans, Ferri et al.48 demonstrated a negative 
correlation between total glucose uptake and circulating ET-1 levels in type 2 diabetes. Fur-
thermore, ET-1 interferes with glucose metabolism as shown by a drop in splanchnic glucose 
production and peripheral glucose utilization during ET-1 infusion in healthy subjects.109 The 
notion that ET-1 modulates insulin sensitivity was supported by the finding that ET-1 re-
duced insulin sensitivity in healthy volunteers.110 Furthermore, the ET-1 precursor, big ET-1, 
reduced insulin sensitivity via an action mediated by the ETA receptor in healthy subjects.
111 
Selective ETA receptor blockade was shown to augment insulin-mediated glucose uptake in 
obese but not lean subjects.112 The metabolic role of ET-1 in relation to its vascular effects in 
subjects with insulin resistance is mainly unknown, however. Further studies are therefore 
needed to elucidate the involvement of ET-1 in the regulation of glucose uptake in subjects 
with glucometabolic perturbations.
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AIMS
The overall aim of these studies was to test the hypothesis that ET-1 is of importance for the 
development of endothelial dysfunction and insulin resistance. Based on this, the specific 
aims were to investigate:
Whether ET receptor blockade enhances endothelium-dependent vasodilatation in 1. 
individuals with insulin resistance and whether such an effect is mediated via selective 
ETA or dual ETA/ETB receptor blockade (I)
Whether ET (selective ET2. A and dual ETA/ETB) receptor blockade improves insulin 
sensitivity in patients with insulin resistance and coronary artery disease (II)
Whether ET-1 regulates skeletal muscle glucose uptake 3. in vivo and in vitro (III, IV)
The molecular mechanisms behind the effect of ET-1 on glucose uptake in cultured 4. 
skeletal muscle cells (III, IV)
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MATERIAL AND METHODS
Study subjects
All the investigations were carried out in accordance with the Declaration of Helsinki and were 
approved by the ethics committee at Karolinska Institutet. The participants were informed of 
the nature, purpose and possible risk involved in the study before giving informed consent.
Study I
Twenty male subjects were recruited from the registry at the Department of Endocrinology 
at Karolinska University Hospital in Stockholm. All the subjects were clinically healthy and 
had no previous history of any cardiovascular disease. All the participants had previously 
undergone an evaluation of insulin sensitivity using the hyperinsulinemic-euglycemic clamp 
method. Subjects with an M-value of <6 or >11 underwent a second clamp within the protocol 
of this study to create two separate groups with an insulin-resistant and an insulin-sensitive 
phenotype. Baseline characteristics of the subjects are presented in Table 1. Twelve subjects 
with a low M-value (insulin resistant) and eight subjects with a high M-value (insulin sensitive) 
were included. Individuals with insulin resistance had significantly higher plasma glucose 
than the insulin-sensitive individuals at 120 min following an oral glucose loading (OGTT). 
Furthermore, the insulin-resistant group had higher insulin levels at baseline and after 30 
and 120 min following the oral glucose loading than the insulin-sensitive group. Body mass 
index, total cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG) 
were significantly higher in the insulin-resistant group (Table 1). There were no significant 
differences in HDL levels between the two groups (Table 1).
Study II
Seven patients (58±2 yr, BMI 31.7±2.6) with a previous history of impaired glucose 
tolerance and coronary artery disease were recruited. Impaired glucose tolerance was defined 
as blood glucose of ≥7.8 mmol/l two hours after an oral glucose loading (75 g). Patients were 
classified as having diabetes mellitus if their fasting blood glucose exceeded 6.0 mmol/l 
(on at least two occasions) or their blood glucose concentration was >11.0 mmol/l two 
hours after an oral glucose loading. Based on these criteria, five patients were classified as 
diabetic and two as having impaired glucose tolerance. Coronary artery disease was defined 
as a history of previous myocardial infarction or significant coronary stenosis verified by 
coronary angiography. The patients were taking aspirin (n=7), statins (n=6), fibrates (n=1), 
angiotensin-converting enzyme (ACE) inhibitors (n=5), beta-blockers (n=7) and oral anti-
diabetics (n=5). Their average total, LDL and HDL cholesterol levels were 4.0±0.3, 2.3±0.3 
and 0.9±0.1 mmol/l respectively. Their average serum creatinine was 87±5 µmol/l.
Study III
Eleven sedentary male subjects (61±3 yr, BMI 28.4±1.6 kg/m2) with insulin resistance as 
assessed by either hyperinsulinemic-euglycemic clamp (total body glucose uptake <6 mg/kg/
min; n=8) or homeostasis model assessment of insulin resistance (HOMA >2.5; n=3) were 
recruited. Six of the subjects had hypertension and two had had a prior myocardial infarction. 
The subjects were taking aspirin (n=1), ACE inhibitors or angiotensin receptor antagonists 
Alexey Shemyakin
18
(n=2), beta-blockers (n=1) or calcium channel blockers (n=1). Their average total LDL 
and HDL cholesterol levels were 5.1±0.4, 3.2±0.2 and 1.2±0.4 mmol/l respectively. Their 
average triglyceride level was 1.4±0.6 mmol/l. Their average glycated hemoglobin (HbA1c), 
C-reactive protein (CRP) and plasma ET-1 levels were 4.7±0.2 %, 1.8±1.3 mg/l and 2.9±0.3 
pmol/l respectively. For the in vitro part of the study, muscle biopsies (rectus abdominis) 
were obtained from 8 subjects during planned abdominal surgery. The subjects did not have 
any metabolic disorders.
Study IV
Nine sedentary male subjects (62±7 yr, BMI 27.8±1.9 kg/m2) with insulin resistance as 
determined by either euglycemic-hyperinsulinemic clamp (total body glucose uptake <6 mg/
kg/min; n=6) or homeostasis model assessment of insulin resistance (HOMA >2.5; n=3), who 
participated in Study III, were recruited for this study. For the in vitro part of the study, muscle 
biopsies (rectus abdominis) were obtained from 19 subjects without any metabolic disorders 
during planned abdominal surgery (58±3 yr, BMI <25 kg/m2). To investigate differences 
between subjects with type 2 diabetes and healthy controls, muscle biopsies (vastus lateralis) 
Table 1.  Baseline characteristics of subjects in Study I.
Insulin resistant 
(n=12)
Insulin sensitive 
(n=8)
p-value
M-value (mg/kg/min) 5.5 ± 1.9 12.5 ± 3.9 <0.001
Age (years) 53 ± 6 54 ± 4.7 =ns
Weight (kg) 90 ± 10 82 ± 14.6 =ns
Height (m) 1.80 ± 0.1 1.85 ± 0.08 =ns
Body mass index (weight/height2) 27.8 ± 3.4 23.8 ± 3.0 <0.05
Mean arterial pressure (mmHg) 93 ± 9 93 ± 9 =ns
Smokers (no.) 0 0
Ex-smokers (no.) 6 3
Non-smokers (no.) 6 5
Total cholesterol (mmol/l) 6.4 ± 0.5 5.5 ± 1.0 <0.01
LDL (mmol/l) 4.5 ± 0.5 3.6 ± 0.8 <0.01
HDL (mmol/l) 1.2 ± 0.3 1.4 ± 0.3 =ns
TG (mmol/l) 1.6 ± 0.5 0.9 ± 0.2 <0.01
OGTT 0' (plasma glucose, mmol/l) 5.2 ± 0.8 5.2 ± 0.4 =ns
OGTT 30' (plasma glucose, mmol/l) 8.2 ± 1.5 7.9 ± 0.7 =ns
OGTT 120' (plasma glucose, mmol/l) 7.5 ± 1.4 5.5 ± 0.9 <0.01
Insulin 0' (µU/ml) 15.2 ± 5.9 8.9 ± 2.4 <0.01
Insulin 30' (µU/ml) 66.7 ± 38.0 35.8 ± 9.4 <0.05
Insulin 120' (µU/ml) 94.0 ± 71.0 37.2 ± 13.9 <0.01
Values are means ± SD
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were also obtained from 11 male subjects with type 2 diabetes (60±2 yr, BMI 29±1 kg/
m2, HOMA=4.3±1.9) and 11 male subjects with normal glucose tolerance (64±1 yr, BMI 
28±1 kg/m2, HOMA=2.0±0.5) under local anesthesia (Lidocaine hydrochloride 5 mg/ml) 
following an overnight fast.
Blood flow measurements
All the investigations were performed with the subjects in the supine position in a quiet 
laboratory with a controlled temperature. The subjects arrived at the laboratory in the 
morning, were instructed not to use caffeine and nicotine-containing products on the study 
day and all medication was withheld on the study day.
Venous occlusion plethysmography (I, III, IV)
Forearm venous occlusion plethysmography is one of the “gold standards” in the assessment 
of vascular function and is an accurate, reproducible method with which to assess the effect 
of vasoactive substances in humans in vivo. This method involves tying a strain gauge – 
a stretchable tube containing mercury – around the limb. When venous drainage from the 
arm is briefly interrupted with inflatable cuffs, arterial inflow remains unaffected, thereby 
resulting in a linear increase in forearm volume over time, which is proportional to arterial 
blood inflow, until venous pressure rises towards the occluding pressure. Changes in limb 
circumference alter the cross-sectional area of the strain gauge and thereby the electrical 
resistance of the mercury, which can be recorded as an analog voltage signal. In our studies, 
forearm blood flow (FBF) was measured simultaneously in both arms using a mercury-in-
silastic strain gauge applied around the widest part of the forearm. A cuff placed around the 
upper arm was inflated to 50 mmHg for 10 sec to obstruct the venous outflow during the 
recording of FBF. The circulation of the hands was occluded by inflating a wrist cuff to 30 
mmHg above systolic blood pressure. FBF values were obtained from four to eight inflow 
measurements during two minutes of recording. A percutaneous catheter was inserted under 
local anesthesia in the proximal direction into the brachial artery of the non-dominant arm for 
infusions and blood sampling. Another catheter was inserted in the distal direction of a deep 
cubital vein, draining mainly skeletal muscle tissue, on the ipsilateral arm for collection of 
blood samples. Endothelium-dependent vasodilatation (EDV) was determined by an infusion 
of acetylcholine into the brachial artery. This was followed by an infusion of the NO donor 
sodium nitroprusside (SNP) for the determination of endothelium-independent vasodilatation 
(EIDV). 
Dye dilution technique (II)
The dye dilution method for measuring blood flow is based on rapidly injecting a known 
quantity of a dye at one site into the circulatory system and withdrawing blood at a distal site to 
determine a concentration curve for the dye. Two thin catheters were inserted percutaneously 
into one antecubital vein on each arm for infusions. Another catheter was introduced into the 
brachial artery for sampling blood and measuring systemic arterial blood pressure. Splanchnic 
(SBF) and renal blood flows (RBF) were determined by the constant infusion of cardiogreen 
(CG), and p-aminohippurate (PAH) and the hematocrit. Sixty minutes after catheterization 
(and the initiation of the PAH and, 10 min later, the CG infusion), blood samples for the 
determination of CG and PAH were drawn from the catheters for basal measurements. 
Table 1.  Baseline characteristics of subjects in Study I.
Insulin resistant 
(n=12)
Insulin sensitive 
(n=8)
p-value
M-value (mg/kg/min) 5.5 ± 1.9 12.5 ± 3.9 <0.001
Age (years) 53 ± 6 54 ± 4.7 =ns
Weight (kg) 90 ± 10 82 ± 14.6 =ns
Height (m) 1.80 ± 0.1 1.85 ± 0.08 =ns
Body mass index (weight/height2) 27.8 ± 3.4 23.8 ± 3.0 <0.05
Mean arterial pressure (mmHg) 93 ± 9 93 ± 9 =ns
Smokers (no.) 0 0
Ex-smokers (no.) 6 3
Non-smokers (no.) 6 5
Total cholesterol (mmol/l) 6.4 ± 0.5 5.5 ± 1.0 <0.01
LDL (mmol/l) 4.5 ± 0.5 3.6 ± 0.8 <0.01
HDL (mmol/l) 1.2 ± 0.3 1.4 ± 0.3 =ns
TG (mmol/l) 1.6 ± 0.5 0.9 ± 0.2 <0.01
OGTT 0' (plasma glucose, mmol/l) 5.2 ± 0.8 5.2 ± 0.4 =ns
OGTT 30' (plasma glucose, mmol/l) 8.2 ± 1.5 7.9 ± 0.7 =ns
OGTT 120' (plasma glucose, mmol/l) 7.5 ± 1.4 5.5 ± 0.9 <0.01
Insulin 0' (µU/ml) 15.2 ± 5.9 8.9 ± 2.4 <0.01
Insulin 30' (µU/ml) 66.7 ± 38.0 35.8 ± 9.4 <0.05
Insulin 120' (µU/ml) 94.0 ± 71.0 37.2 ± 13.9 <0.01
Values are means ± SD
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This was followed by sampling every 20 min up to 60 min. This method has been evaluated 
previously using the introduction of hepatic and renal vein catheters to ascertain that fractional 
uptake, equal to the arterio-venous difference divided by the arterial concentration, of CG and 
PAH was not influenced by the infusion of the ET-1 blockers113 or the clamp procedure.111 
The hematocrit was analyzed with a microcapillary hematocrit centrifuge and corrected for 
trapped plasma. Splanchnic (SplVR) and renal vascular resistances (RVR) were calculated as 
mean arterial pressure divided by SBF or RBF respectively and measured at the baseline and 
thereafter every 20 min.
Glucose uptake measurements
Hyperinsulinemic-euglycemic clamp (II)
The hyperinsulinemic-euglycemic clamp is the “gold standard” for investigating and quantify-
ing total body glucose uptake and insulin sensitivity. The principle of this method is to measure 
the amount of glucose necessary to compensate for an increased insulin level without causing 
hypoglycemia. Two thin catheters were inserted percutaneously into one antecubital vein on 
each arm for infusions. Another catheter was introduced into the brachial artery for blood sam-
pling. Insulin, dissolved in 0.9% saline and blood, was infused at a rate corresponding to 804 
mU/m2 body surface area during the first 8 min, followed by 40 mU/m2/min for 112 min. The 
fasting blood glucose level was maintained by adjusting the infusion rate of a 20% glucose so-
lution. Arterial blood samples were taken every 5 min for the determination of blood glucose.
Forearm glucose uptake (III, IV)
Since skeletal muscle accounts for a major part of glucose uptake, the rate of glucose utilization 
in skeletal muscle is of great importance for the determination of insulin sensitivity. We there-
fore used the forearm model in which it is possible to determine local arterio-venous concentra-
tion differences and blood flow in order to calculate glucose uptake in a vascular bed mainly 
supplying skeletal muscle.114 During venous occlusion plethysmography, FBF was measured 
and arterial and deep venous blood samples were collected. Forearm glucose uptake (FGU) 
was calculated according to the following formula: (arterial – venous glucose concentration) × 
blood flow × (1-hematocrit).
Glucose uptake in skeletal muscle cell cultures (III, IV)
Glucose uptake in skeletal muscle cell cultures was assessed using isotope-labeled glucose. 
Muscle biopsies were collected in cold PBS supplemented with 1% PeSt (100 U/ml penicillin 
and 100 µg/ml streptomycin). Satellite cells were isolated and cultured to form myotubes as de-
scribed.115 Myotubes were incubated in serum-free medium overnight before each experiment. 
ET-1 or vehicle was added in the absence or presence of the dual ETA/ETB receptor antagonist 
bosentan (3 μM) for the times indicated. Bosentan was added 30 min before ET-1. Control cells 
were exposed to the vehicle for the same length of time. Where indicated, insulin (60 nM) was 
added for 30 min. Overnight serum-starved myotubes (in the presence or absence of ET-1) 
were stimulated with or without insulin in KREBS buffer. Cells were then incubated with 10 
µM 2-deoxy[3H]glucose (1µCi/ml) for 15 min at 37ºC. Each experiment was carried out on 
triplicate wells. Cells were then rapidly rinsed 4 times with ice-cold PBS and solubilized with 
1 ml 0.4 N NaOH. 0.5 ml of lysate was transferred into scintillation vials and [3H] measured in 
a scintillation counter.
         Endothelin-1 and insulin resistance
21
Protein expression by Western blotting (III, IV)
Protein expression was quantified in lysates from skeletal muscle cell cultures using the Western 
blot technique. An aliquot of muscle cell lysate (20 µg protein) was mixed in Laemmli sample 
buffer containing β-mercaptoethanol. Proteins were separated by 7.5% SDS-PAGE, transferred 
to polyvinylivenediflouride membrane (Millipore) and blocked in 7.5% non-fat dried milk in 
Tris-buffered saline with 0.02% tween (TBST) for 2 hours at room temperature. Membranes 
were incubated overnight at 4°C with antibodies against human ETA and ETB receptors (1:200, 
Alomone Labs), phospho-specific antibodies against phospho-IRS1 Ser636 (1:1000), phospho-
Akt Ser473 (1:1000), phospho-ERK1/2, p42/44 MAPK kinase Thr202/Tyr204 (1:1000), phospho-
AMPK Thr172 (1:1000), Akt (1:1000), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(1:1000), or pan-actin (1:1000), all from Cell Signaling Technology). After washing in TBST, 
the membranes were incubated with horseradish peroxidase anti-rabbit IgG for all the target 
proteins (1:25000, Bio-Rad) for 1 hour at room temperature, followed by additional washing. 
Proteins were visualized by enhanced chemiluminescence (Amersham) and quantified using 
densitometry and Molecular Analyst Software (Bio-Rad).
Study protocols
Study I
All the study subjects participated in two venous occlusion plethysmography protocols (Fig. 3) 
separated by at least two weeks. In Protocol A, the ETA receptor antagonist BQ123 (10 nmol/
min) was administered. In Protocol B, the combination of BQ123 (10 nmol/min) and the ETB 
receptor antagonist BQ788 (5 nmol/min) was given by intra-brachial infusion at a rate of 0.5 
ml/min. The order of treatment was randomized. The doses of the antagonists were based 
on previous studies.65, 70 On both occasions, basal FBF was recorded during an infusion of 
saline for two minutes at a rate of 2.5 ml/min. Basal endothelium-dependent and –independent 
vasodilatation was determined as described above before and following 60 min of ET receptor 
antagonist infusion. FBF was determined every 10 min during the 60-min infusion of the 
antagonists. Venous plasma glucose samples were collected before and at 60 min of ET receptor 
blockade. Blood pressure and heart rate were determined from the arterial catheter at baseline 
and after the infusions of acetylcholine, SNP and the ET receptor antagonists.
Figure 3. Study protocol for venous occlusion plethysmography in Study I.
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Study II
The study consisted of three different hyperinsulinemic-euglycemic clamp protocols: (A) a 
clamp with an infusion of the ETA receptor antagonist BQ123, (B) a clamp with a combined 
infusion of BQ123 and the ETB receptor antagonist BQ788 and (C) a control clamp with saline 
infusion. There was at least one week between the clamp studies. The investigations were 
performed in random order and the patients were unaware of the order of the clamps and were 
thus blinded to the treatments. In Protocol A, the ETA receptor antagonist BQ123 was infused 
at a rate of 5 nmol/kg/min. In Protocol B, the ETB receptor antagonist BQ788 was infused at a 
rate of 4 nmol/kg/min, together with BQ123 (5 nmol/kg/min). The infusions of the antagonists 
started 60 min into the clamp and were maintained for 15 min (Fig. 4). The doses of BQ123 
and BQ788 were based on previous studies demonstrating effective hemodynamic responses 
and antagonism of vascular effects evoked by ET-1.113, 116-118 In Protocol C, an infusion of saline 
was started at 60 min into the clamp and was maintained for 15 min. Total body glucose uptake 
(M) values were calculated during three 20-min periods (Period I, II and III respectively; Fig. 4) 
during and following the administration of saline/antagonists and then corrected for the mean 
of the two plasma insulin values obtained during each period (M/I value).
Study III
Each patient was investigated on three different occasions using different venous occlusion 
plethysmography protocols (Fig. 5). The investigations were performed in random order, 
the subjects were unaware of this order and were thus blinded to the treatments. The 
investigations were separated by at least one week. In Protocol A, saline was infused for 
30 min (60 ml/hour), followed by a 60-min infusion of the ETA receptor antagonist BQ123 
Figure 4. Study protocols for the hyperinsulinemic-euglycemic clamp in Study II. An 
infusion of saline/ET receptors antagonists was given for 15 min. 
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(10 nmol/min) and the ETB receptor antagonist BQ788 (10 nmol/min). This was followed 
by a co-infusion of the antagonists and insulin (0.05 mU/kg/min; 20 ml/hour) for another 
60 min. In Protocol B, saline was infused for 30 min, followed by an insulin infusion 
(0.05 mU/kg/min) for 120 min. In Protocol C, saline was infused for 30 min, followed 
by an infusion of insulin alone for 60 min. This was followed by a co-infusion of ET-1 
(20 pmol/min) together with insulin for 60 min. In seven subjects, the ET-1 infusion was 
prolonged for an additional 15 min to investigate possible time-dependent differences. 
A saline infusion was given to keep the infusion volume at the same rate (1 ml/min). All 
infusions were given into the brachial artery. Deep venous and arterial blood samples were 
collected during the protocols for the determination of forearm glucose uptake. 
Study IV
FBF was assessed using venous occlusion plethysmography. After the insertion of the 
catheters, an infusion of saline (60 ml/hour) was started, followed by an infusion of ET-1 
(20 pmol/min) for 120 min. EDV and EIDV were determined as described above. Arterial 
and venous blood samples were collected repeatedly during the study protocol for the 
determination of glucose and insulin levels.
Figure 5. Study protocols for venous occlusion plethysmography in Study III.
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Biochemical analysis
Fasting venous blood samples for total LDL and HDL cholesterol, triglycerides and HbA1c 
were assessed according to local laboratory routines. In Studies I and II, plasma glucose 
was analyzed by the azidemethemoglobin method using a HemoCue B-Glucose Analyser 
(HemoCue, Ängelholm, Sweden) with a precision corresponding to an SD of ± 0.3 mmol/L. 
In Studies III and IV, plasma glucose was analyzed by a timed endpoint method using 
Glucose Reagent in conjunction with the SYNCHRON LX® System (Beckman Coulter, 
Fullerton, USA) with a precision corresponding to an SD of ± 0.11 mM. Plasma insulin was 
analyzed using an electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, 
Germany) for the Elecsys® analyzer. CRP was measured using the Behring Nephelometer 
Analyzer II with a particle-enhanced immunonephelometric assay. ET-1 was analyzed by 
radioimmunoassay using commercially available antisera (rabbit anti-ET-1 6901, Peninsula, 
Merseyside, UK) following ethanol extraction.119 The intra-assay and inter-assay variations 
were 7% and 10% respectively.  The hematocrit was analyzed with a microcapillary hematocrit 
centrifuge and corrected for trapped plasma.
Statistical analysis
In all the studies, the results are presented as the mean and standard error of the mean (SEM) 
with the exception for paper I where subject’s baseline characteristics data are presented 
as the mean and standard deviation (SD). Categorical data are expressed as numbers. Two 
grouping variables were compared by Student’s t-test. Mann-Whitney test was used for the 
comparison of protein expression. Comparison of multiple observations was assessed by 
one-way ANOVA for repeated measurements with a post-hoc analysis. Differences between 
the changes in FBF and FGU were assessed by two-way ANOVA. A probability of <0.05 
was considered statistically significant. The clinical part of Studies I and II was powered 
based on an estimate from previous studies.53, 109, 111 Studies III and IV were powered based 
on estimates from Studies I and II. Statistical analyses were performed using GraphPad Prism 
version 4 (GraphPad Software, San Diego, USA).
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RESULTS
In vivo studies
ET-1 and vascular function in insulin resistance
Effect of ET receptor blockade on forearm blood flow and endothelial function 
in insulin-sensitive and insulin-resistant individuals (I, III)
In Study I, basal FBF did not differ significantly between the insulin-sensitive and insulin-
resistant groups. The basal (i.e. before the administration of ET receptor antagonists) response 
to acetylcholine or SNP did not differ between the groups. Selective ETA receptor blockade did 
not influence the vasodilator response to acetylcholine or SNP in either group. Dual ETA/ETB 
receptor blockade significantly enhanced EDV in the insulin-resistant group (Fig. 6A) but not 
in the insulin-sensitive group (Fig. 6B). Furthermore, EDV was significantly greater following 
dual ETA/ETB receptor blockade than following selective ETA receptor blockade (p<0.01). 
Combined ETA/ETB receptor antagonism did not affect EIDV in either the insulin-resistant or 
insulin-sensitive groups. Selective ETA receptor blockade slightly yet significantly increased 
FBF by 18±8% (p<0.05) at 60 min of infusion in the insulin-resistant group. Basal FBF was 
unaffected by dual ETA/ETB receptor blockade in either group. 
In Study III, there were no significant differences in basal FBF between the three protocols. 
Dual ETA/ETB receptor blockade increased FBF by 30% (p<0.05) at 60 min of infusion. The 
addition of insulin co-infused with the ET receptor antagonists further increased FBF by 16% 
(p<0.05 vs. ET blockade alone). Insulin infusion alone for 120 min did not affect FBF.
Figure 6. Change in forearm blood flow (FBF) induced by acetylcholine (Ach) during NaCl 
and following dual ETA/ETB receptor blockade by BQ123 and BQ788 in insulin-resistant 
(Panel A; n=11) and insulin-sensitive (Panel B; n=8) individuals. A significant difference 
was found between the responses to Ach during saline and following BQ123 and BQ788 by 
ANOVA. ns=not significant.
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Effect of ET-1 on forearm blood flow and endothelial function in insulin-
resistant individuals (IV)
The administration of ET-1 reduced FBF by 30% (p<0.01) at 60 min and by 36% (p<0.05) 
at 120 min of infusion as compared to basal values. The infusion of ET-1 markedly inhibited 
acetylcholine-induced vasodilatation (p<0.001; Fig. 7A). In addition, the vasodilator response 
to SNP was slightly yet significantly attenuated by ET-1 (Fig. 7B). Blood pressure and heart 
rate did not change significantly during the administration of ET-1.
Effect of ET receptor blockade on renal and splanchnic blood flow in insulin-
resistant individuals (II)
There was no difference in mean arterial pressure (MAP) between the groups at 60 min of 
hyperinsulinemic-euglycemic clamp (i.e. before the administration of antagonists). However, 
MAP was reduced following the administration of BQ123 (p<0.01) in Protocol A and follow-
ing the administration of BQ123+BQ788 (p<0.05) in Protocol B compared with the saline 
infusion in Protocol C (control clamp). Renal blood flow (RBF) at baseline did not differ 
between the protocols and it did not change in the control or BQ123 clamps. In contrast, RBF 
increased by 24% (p<0.01) following the administration of BQ123+BQ788 (Fig. 8A). RBF 
was significantly higher in Protocol B as compared to the other protocols (p<0.01). There 
were significant differences in renal vascular resistance (RVR) between the clamp protocols 
(Fig. 8B). RVR was significantly lower in Protocol B than in Protocols A and C (p<0.05). 
There were no significant differences in SBF or splanchnic vascular resistance between the 
clamp protocols.
Figure 7. Change in forearm blood flow (FBF) induced by different doses of acetylcholine 
(Ach; Panel A) and sodium nitroprusside (SNP; Panel B) during NaCl and following 30 and 
90 minutes of ET-1 infusion. Significant differences were found between the responses to Ach 
and SNP during saline and following ET-1 infusion by ANOVA. Data are means ± SEM (n=9).
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ET-1 and glucose metabolism in insulin resistance
Effect of ET receptor blockade on whole-body glucose uptake and insulin 
sensitivity in insulin-resistant individuals (II)
Arterial glucose values remained unchanged and did not differ between the clamps. There 
were no differences in arterial insulin levels between the three clamp protocols. Glucose 
uptake and insulin sensitivity were determined during saline infusion in Protocol C (con-
trol clamp) and following ET receptor blockade in the BQ clamps. There were significant 
(p<0.05) differences in total body glucose uptake, M values, between the three clamp proto-
cols (Fig. 9A). The M value was significantly higher in Protocol B (BQ123+BQ788 clamp) 
than in the Protocol C and in comparison with Protocol A (BQ123 clamp; p<0.05). There was 
no difference in M values between the control and the BQ123 clamps. There were differ-
ences in insulin sensitivity, expressed as M/I values, between the three clamps (p<0.02). The 
M/I value was significantly higher in the BQ123+BQ788 clamp than in the control clamp 
(p<0.01) and the BQ123 clamp (p<0.05). The M/I value already tended to be higher at the 
first measurement point during dual receptor blockade with BQ123+BQ788 and it became 
significantly higher in comparison with the other groups at measurement points 2 and 3 (Fig. 
9B). There was no difference between the control clamp and the BQ123 clamp.
Effect of ET-1 and ET receptor blockade on forearm glucose uptake in insulin-
resistant individuals (III, IV)
In Study IV, the infusion of NaCl for 30 min did not affect FGU. ET-1 infusion increased the 
arterio-venous glucose difference by 67% (p<0.05) at 90 min, followed by a decrease to basal 
values at 120 min (p<0.05 baseline vs. 90 min; Fig. 10A). The infusion of ET-1 decreased FGU 
Figure 8. Changes in renal blood flow (RBF; Panel A) and renal vascular resistance (RVR; 
Panel B) during selective ETA receptor blockade (Protocol A), dual ETA+ETB receptor 
blockade (Protocol B) and saline infusion (Protocol C). Hatched bars indicate period of 
saline/antagonist infusion. Significant differences between groups by ANOVA are indicated. 
Data are presented as means and SEM; n= 7.
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from 5.8±2.0 μmol/min x 1000ml at baseline (saline) to 3.4±0.8 μmol/min x 1000ml at 120 
min (p<0.05; Fig. 10B). During the protocol, arterial insulin concentrations decreased from 
81.0±11.0 pM at baseline to 65.7±7.5 pM at 120 min of ET-1 infusion (p<0.05). The arterio-
venous concentration difference of insulin remained unchanged. There was no correlation 
between the reductions in arterial insulin concentration and FGU (r=0.05, p=0.91).
Figure 9. Total body glucose uptake (M; Panel A) and insulin sensitivity (M/I; Panel B) 
values in the three sampling periods during selective ETA receptor blockade in Protocol A 
(BQ123), during dual ETA/ETB receptor blockade in Protocol B (BQ123+788) and during 
saline infusion in Protocol C (NaCl). Values were calculated during three 20-min periods 
following the administration of saline/antagonists and were then corrected for the mean of 
the two plasma insulin values obtained during each period (M/I). Significant differences 
between groups are indicated. Data are presented as means and SEM; n = 7.
Figure 10. Arterio-venous glucose differences during NaCl infusion and following a 
120-min infusion of ET-1 (Panel A). Forearm glucose uptake during NaCl infusion and 
following a 120-min infusion (Panel B). *p<0.05, ***p<0.001 by one-way ANOVA. Data 
are means ± SEM (n=9).
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In Study III, the infusion of ETA/ETB receptor antagonists in Protocol A increased FGU from 
5.1±1.0 at baseline (saline) to 8.3±1.1 μmol/min x 1000ml at 60 min (p<0.05; Fig. 11A). The 
co-administration of insulin further increased glucose uptake to 15.7±1.8 µmol/min/1000ml 
(p<0.001; Fig. 11B). The insulin infusion in Protocol B increased FGU from 4.1±1.1 at baseline 
(saline) to 7.7±1.9 μmol/min x 1000ml (p<0.05) at 30 min and to 12.3±1.6 μmol/min x 1000ml 
(p<0.001; Fig 11B) at 60 min. Dual ETA/ETB receptor blockade in combination with insulin 
(Protocol A) resulted in significantly greater FGU than the infusion of insulin alone (Protocol 
B) (Fig. 11B). In Protocol C, the infusion of insulin increased FGU from 7.1±0.7 μmol/min 
x 1000ml at baseline to 17.8±3.0 μmol/min x 1000ml at 60 min of infusion. After 60 min of 
insulin infusion, glucose uptake reached a steady state. ET-1 infusion for 60 min in combination 
with insulin did not affect insulin-stimulated FGU (16.5±2.0 μmol/min x 1000ml). Nor did the 
prolongation of the ET-1 infusion for an additional 15 min in 7 subjects affect FGU.
In vitro studies
ET receptor expression in skeletal muscle cell cultures (IV)
Western blot analysis revealed the expression of ETA and ETB receptors in skeletal muscle 
cell cultures (Fig. 12A and B). ETA receptor expression was higher in cells from subjects 
with type 2 diabetes (T2D) compared with cells from subjects with normal glucose tolerance 
(NGT) (p<0.05; Fig 12A). There was also a trend towards increased expression of ETB recep-
tors in cells from subjects with T2D (p=0.13; Fig 12B).
Effect of ET-1 and ET receptor blockade on glucose uptake in skeletal muscle 
cell cultures (III, IV)
One hour exposure to ET-1 increased glucose uptake in skeletal muscle cells from NGT subjects 
(Fig. 13A and B) and this effect persisted at 1, 2 and 6 hours (p<0.05; Fig. 13A) of incubation 
Figure 11. Forearm glucose uptake during NaCl infusion and following a 60-min infusion 
of the ETA/ETB receptor antagonists BQ123 and BQ788 in Protocol A (Panel A). *p<0.05 
using Student’s t-test. Effect of dual ETA/ ETB receptor blockade (BQ) on basal and insulin-
stimulated glucose uptake in Protocol A in comparison with the effect of insulin alone 
in Protocol B (Panel B). There was a significant difference between the entire protocols 
including all time points by two-way ANOVA. Data are means ± SEM (n=10).
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with ET-1. At 24 hours, ET-1 induced a significant reduction in glucose uptake (Fig. 13A). The 
co-incubation of ET-1 with bosentan (3 µM) for 24 hours completely prevented the inhibitory 
effect of ET-1 on glucose uptake. ET-1 did not further increase insulin-stimulated glucose 
uptake in cells established from subjects with normal glucose tolerance (Fig. 13B). In contrast, 
ET-1 or insulin did not increase glucose uptake in cells from T2D subjects (Fig. 13B).
Effect of ET-1 on insulin signaling 
Incubation with ET-1 for 1 hour reduced insulin-stimulated Akt phosphorylation in a dose-
dependent manner (Fig. 14A). This inhibitory effect of ET-1 was reversed following the 
Figure 12. Western blot analysis of the ETA (Panel A) and ETB (Panel B) receptor expression 
in cells established from subjects with normal glucose tolerance (NGT; n=8) and subjects with 
type 2 diabetes (T2D; n=8). *p<0.05 using the Mann-Whitney test. Data are means ± SEM.
Figure 13.  Panel A. Glucose uptake in skeletal muscle cells at basal state and after 1, 2, 6 
and 24 hours treatment with 10 nM ET-1. *p<0.05 using one-way ANOVA. Data are means 
± SEM (n=3). Panel B. Basal and insulin-stimulated glucose uptake in cells established 
from subjects with normal glucose tolerance (NGT; n=11) and subjects with type 2 diabetes 
(T2D; n=11) under basal conditions and after 1 hour of ET-1 treatment. *p<0.05 using 
Student’s t-test. Data are means ± SEM.
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pre-exposure of muscle cultures to the dual ETA/ETB receptor antagonist bosentan (Fig. 
14A). The effect of ET-1 on insulin-stimulated Akt phosphorylation was evident in cells 
established from both NGT and T2D subjects (Fig. 14B). ET-1 did not affect the basal or 
insulin-stimulated phosphorylation of Akt following 24 hours incubation.
One hour and 24 hours exposure to ET-1 increased the phosphorylation of IRS1 Ser636, an 
effect that was blocked by the pre-exposure of cells to bosentan (Fig. 15A and B). ET-1 
exposure transiently increased the phosphorylation of ERK1/2, peaking at 5 min and returning 
to baseline by 20 min. No effect of ET-1 was noted on the phosphorylation of AMPK at time 
points from 3 to 20 min up to 24 hours (data not shown).
Figure 14.  Panel A. The basal and insulin-stimulated expression of phosphorylated Akt under 
control conditions and after 1 hour exposure to ET-1 (1, 10 and 100 nM) in the absence and 
presence of the ET receptor antagonist bosentan (3 µM). ***p<0.001 using a one-sample t-test. 
NS=not significant. Data are means ± SEM (n=4-19). Panel B. The insulin-stimulated expression 
of phosphorylated Akt under control conditions and after 1 hour exposure to ET-1 (10 nM) in 
cells established from subjects with normal glucose tolerance (NGT; n=5) and subjects with 
type 2 diabetes (T2D; n=4). *p<0.05 using a one-sample t-test. Data are means ± SEM.
Figure 15.  Panel A. The basal and insulin-stimulated expression of phosphorylated IRS1, 
under control conditions and after 1 hour exposure to ET-1 in the absence and presence of 
the ET receptor antagonist bosentan (3 µM). *p<0.05 using the Mann-Whitney test. Data are 
means ± SEM (n=5). Panel B.  Basal and insulin-stimulated IRS-1 ser636 phosphorylation 
under control conditions and after 24 hours exposure to ET-1 (10 nM) or a combination of 
ET-1 and bosentan (3 µM). Data are means ± SEM (n=3).
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GENERAL  DISCUSSION
Effects of ET-1 on blood flow and vascular function in insulin-sensitive and 
insulin-resistant individuals
Growing evidence suggests that ET-1 plays an important role in the development of endothe-
lial dysfunction. The major mechanism for this pathophysiological process is the reduction of 
NO bioavailability: ET-1 either reduces NO production (via the inhibition of eNOS activity) 
or increases its degradation (via the formation of oxygen radicals). It has been suggested that 
the increased production of ET-1 is part of the endothelial dysfunction in insulin resistance.33 
In fact, there are a number of studies demonstrating that different pathological conditions as-
sociated with the presence of insulin resistance, such as type 2 diabetes,48 obesity,49 essential 
hypertension50 and coronary artery disease,51 are associated with elevated plasma levels of 
ET-1. Despite the fact that elevated circulating plasma levels of ET-1 were not found in insu-
lin-resistant individuals in Study I, dual ETA/ETB receptor blockade enhanced the vasodilator 
response to acetylcholine in this group. Since the vasodilator response to acetylcholine is 
dependent on the release of endothelium-derived NO,53 the present observation suggests that 
dual ETA/ETB receptor blockade enhances NO availability in subjects with insulin resistance. 
Endothelium-dependent vasodilatation was unaffected by either selective ETA or dual ETA/
ETB receptor blockade in insulin-sensitive individuals matched for age and gender. Taken 
together, these data could indicate the presence of enhanced activity of endogenous ET-1 
in insulin-resistant subjects without clinical signs of cardiovascular disease. Moreover, the 
insulin-resistant subjects included in this study did not display impairment in basal endothe-
lium-dependent vasodilatation, indicating that increased ET-1 activity is an early vascular 
finding in insulin resistance. In Study IV, we demonstrate that exogenous ET-1 impairs both 
endothelium-dependent and -independent vasodilatation in the forearm of subjects with in-
sulin resistance. This result extends previous findings that exogenous ET-1 markedly reduces 
endothelium-dependent vasodilatation in healthy subjects.53
In Study II, we observed that dual ETA/ETB but not selective ETA, receptor blockade increased 
renal blood flow and reduced renal vascular resistance in subjects with insulin resistance and 
cardiovascular disease. These changes in hemodynamic parameters support a role for ET-1 
in the regulation of vascular tone in this patient group. Splanchnic blood flow and splanchnic 
vascular resistance were unaffected by ET antagonists, suggesting regional differences in the 
influence of ET-1 on vascular tone. However, these results contrast with those previously 
obtained in patients with chronic renal failure and hypertension, where selective ETA, but 
not dual ETA/ETB, receptor blockade increased renal blood flow and reduced renal vascular 
resistance.117 Important differences between these studies are that patients in our study had 
normal renal function, based on serum creatinine levels, and normal blood pressure. In Study 
III, dual ETA/ETB receptor blockade significantly increased forearm blood flow in insulin-
resistant individuals. Interestingly, the co-infusion of ET receptor antagonists with insulin 
resulted in a significant additional increase in blood flow, despite the fact that insulin did 
not affect forearm blood flow, which is in accordance with previous studies.120, 121 Although 
a carry-over effect by the ET receptor blockade cannot be ruled out, this observation may 
indicate the unmasking of insulin-mediated vasodilatation. These data are in agreement with 
previous experimental studies, suggesting that insulin induces vasodilatation only after the 
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blockade of ET receptors in insulin resistance,122, 123 via an effect coupled to an increase in 
NO bioavailability.124
It is often assumed that most of the pathological effects of ET-1 are mediated via the 
stimulation of the ETA receptor and that the blockade of endothelial ETB receptors may have 
a detrimental effect on vascular function.57 Despite this, in Study I, selective ETA receptor 
blockade did not influence endothelium-dependent vasodilatation in the insulin-resistant 
group. It could therefore be speculated that the blockade of both the ETA and the ETB 
receptor is needed to enhance endothelial function in this group. The present study extends 
the findings of improved endothelium-dependent vasodilatation by dual ETA/ETB receptor 
blockade in patients with hypertension55 and atherosclerosis.54 It could be hypothesized that 
this effect is related to the increased expression of ETB receptors, which has been reported 
in atherosclerotic human arteries.67 The finding that dual ETA/ETB receptor blockade did 
not result in impaired vascular function in the healthy insulin-sensitive group, despite the 
blockade of the ETB receptor, is also of importance. The exact mechanism behind the effect 
of ET receptor blockade on endothelium-dependent vasodilatation is not fully understood and 
could be attributed to several factors. One possibility is that ET receptor blockade up-regulates 
NOS. The dual ET receptor antagonist bosentan was shown to increase the expression of 
endothelial NOS.56 Furthermore, NOS activity is stimulated by dual ET receptor blockade.57 
Another possibility is that ET-1 increases the formation of reactive oxygen species which will 
result in the reduced bioactivity of NO.125-127 ET receptor antagonism may therefore enhance 
endothelium-dependent vasodilatation via the reduced formation of reactive oxygen species. 
From Studies I, II, III and IV, it could be concluded that ET-1 impairs basal vascular tone and 
endothelium-dependent vasodilatation in subjects with insulin resistance. Dual ETA/ETB but 
not selective ETA, receptor blockade improves endothelial function and increases basal blood 
flow in this group. 
ET-1 and glucose metabolism in insulin resistance in vivo and in vitro
Several studies indicate that ET-1 is able to interfere with glucose metabolism. The 
administration of exogenous ET-1 or its precursor, big ET, was shown to reduce insulin 
sensitivity in healthy humans110, 111 and in experimental animals.108 Furthermore, a negative 
correlation between total glucose uptake and circulating ET-1 levels was found in diabetic 
patients.48 It has been reported that exogenous ET-1 exerts a biphasic effect on glucose 
metabolism in the perfused rat hind limb with the stimulation of glucose uptake at a low dose 
and the inhibition of glucose uptake at a high dose.128 ETA receptor blockade was shown to 
increase glucose uptake during a hyperinsulinemic-euglycemic clamp in obese individuals.112 
Studies of isolated skeletal muscle strips suggest that this effect is independent of a reduction 
in skeletal muscle blood flow and implies a direct influence by ET-1 on insulin-stimulated 
glucose transport.108 Accordingly, ET-1 reduces the expression of IRS1 and insulin-stimulated 
Akt phosphorylation in skeletal muscle vascular smooth muscle cells.107, 108 Furthermore, 
ET-1 impairs glucose transporter GLUT4 trafficking in rat adipocytes.106
Based on these previous observations, we hypothesized that endogenous ET-1 affects insulin-
stimulated glucose uptake in patients with insulin resistance and coronary artery disease. In 
Study II, we demonstrated that dual ETA/ETB receptor blockade acutely increased total body 
glucose uptake and insulin sensitivity in obese patients with insulin resistance and coronary 
artery disease. On the other hand, no improvement was observed following selective ETA 
receptor blockade. This is in accordance with the finding in Study I, where dual ETA/ETB 
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receptor blockade, but not selective ETA, improved endothelium-dependent vasodilatation. 
These observations indicate that ET-1 contributes to insulin resistance and that both the ETA 
and the ETB receptor need to be blocked to achieve this effect. 
Since skeletal muscle is a primary site of glucose uptake, we used the forearm model in which 
it is possible to determine local arterio-venous concentration differences and blood flow to 
calculate glucose uptake in a vascular bed mainly supplying skeletal muscle114 in Studies III 
and IV. In Study III, dual ETA/ETB receptor blockade not only increased insulin-stimulated 
skeletal muscle glucose uptake in subjects with insulin resistance, it also significantly increased 
glucose uptake per se. When the ET receptor antagonists were co-infused with insulin, glucose 
uptake was significantly greater than during the infusion of insulin alone. Collectively, these 
observations suggest that dual ETA/ETB receptor blockade augments basal glucose uptake 
and facilitates insulin-stimulated glucose uptake in the skeletal muscle tissue of subjects with 
insulin resistance. In Study III, the administration of endogenous ET-1 for 60 min did not 
affect forearm glucose uptake, which is in contrast to previous observations showing that the 
administration of exogenous ET-1 or its precursor, big ET, reduces insulin sensitivity in healthy 
humans110, 111 and in experimental animals.108 We therefore hypothesized that the lack of ET-1 
effect on forearm glucose uptake could be attributed to the constant intra-arterial infusion of 
insulin, which is known to increase blood flow in an NO-dependent manner and to stimulate 
glucose uptake in skeletal muscle.83 To elucidate this, we designed Study IV, where we used the 
same forearm model to study the independent metabolic actions of ET-1 in the same subjects. In 
this study, the exogenous infusion of ET-1 resulted in a significant reduction in forearm glucose 
uptake following 2 hours infusion. Despite an overall reduction in forearm glucose uptake, 
arterio-venous glucose concentrations were significantly increased during the first 90 min of 
ET-1 infusion, after which they fell to basal levels at 2 hours. This could indicate an initial 
ET-induced stimulation of glucose uptake in skeletal muscle, which may be obscured by the 
parallel reduction in blood flow. One limitation of this study is that we did not obtain steady-
state insulin levels. During the protocol, arterial insulin levels fell by 19%. The underlying 
cause of this change is unknown, but it may partly explain the reduction in glucose uptake. 
However, no correlation between the reduction in insulin levels and the ≈ 40% reduction in 
forearm glucose uptake was observed. The reduction in forearm glucose uptake may therefore 
be related to other factors such as direct effects by ET-1 on skeletal muscle insulin signaling 
and blood flow.
To obtain further insight into the complex nature of these changes in vivo, we studied the effect 
of ET-1 in cultured human skeletal muscle, giving us an opportunity to determine any direct 
and flow-independent effects of ET-1 on glucose uptake. In Study IV, we demonstrated that 
both ETA and ETB receptors are expressed on skeletal muscle cells and that there is therefore a 
rationale for a direct effect of ET-1 in cell cultures. In Study III, 24 hours incubation with ET-1 
induced a marked inhibition of basal and insulin-stimulated glucose uptake in cultured skeletal 
muscle cells, obtained from healthy subjects. This observation is in accordance with previous 
data in adipocytes129 and indicates that ET-1 can exert its metabolic properties independent of 
its vasoconstricting effects. The inhibitory effect of ET-1 on glucose uptake was completely 
antagonized by dual ETA/ETB receptor blockade, suggesting a receptor-mediated effect of 
ET-1, and this supports our in vivo observation in Study III. In Study IV, we investigated the 
temporal effect of ET-1 on glucose uptake in skeletal muscle cell cultures. In cells obtained 
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from healthy, normal glucose-tolerant subjects, acute ET-1 exposure (1 hour up to 6 hours 
exposure) increased glucose uptake. This observation is in agreement with previous data 
obtained in rodent muscle.108 It is therefore possible to speculate that, in skeletal muscle, ET-1 
exerts a biphasic effect with an initial stimulation, followed by a reduction in glucose uptake. 
Interestingly, in Study IV, incubation with ET-1 did not affect glucose uptake in cells cultured 
from individuals with type 2 diabetes, indicating a quantitative and qualitative difference in 
the effect of ET-1 on glucose metabolism between insulin-sensitive and insulin-resistant states. 
Furthermore, the expression of ETA receptors was increased in cells from subjects with type 
2 diabetes. Whether this difference influences alterations in glucose uptake remains to be 
elucidated in further studies. Collectively, the data indicate that prolonged exposure to ET-1 
reduces total body and skeletal muscle glucose uptake and that this effect is antagonized by dual 
ETA/ETB receptor blockade.
ET-1 and insulin signaling
We also aimed to dissect molecular signaling events underlying the ET-1 effects on glucose 
uptake. Since the metabolic IRS1-PI3 kinase-Akt  branch of insulin signaling pathways plays 
a pivotal role in promoting  insulin-mediated glucose uptake,95 it is tempting to speculate that 
an  ET-1-mediated reduction in skeletal muscle glucose uptake occurs via the modification 
of IRS1 and Akt phosphorylation. In Studies III and IV, both acute and prolonged ET-1 
exposure increased IRS1 serine phosphorylation on a negative regulating site, Ser636, which 
acts as a negative feedback control mechanism reducing IRS1 tyrosine phosphorylation 
following prolonged insulin exposure.130 This effect was prevented by the ETA/ETB receptor 
antagonist bosentan. In Study IV, we demonstrate that cells incubated with ET-1 for 1 hour 
reduced insulin-stimulated Akt phosphorylation via a dose-dependent and receptor-dependent 
mechanism. This observation is in line with previous observations in rat skeletal muscle and 
vascular smooth muscle cells.107, 108 However, this is not the case in adipocytes, in which ET-1 
mediates an impairment in glucose transport via PI3K-independent mechanisms.106, 131 In Study 
III, we observe that this inhibitory effect of ET-1 on Akt phosphorylation is diminished after 
the prolonged 24 hours incubation. Furthermore, in Studies III and IV, a reduction in glucose 
uptake in skeletal muscle cells derived from healthy subjects was only evident following 24 
hours of ET-1 exposure.
Akt has been shown to play an important role in promoting the metabolic actions of insulin, 
including GLUT4 translocation.132 Despite this, there is increasing evidence that Akt activation 
alone is not sufficient for insulin effects on glucose transport.133-135 Furthermore, the insulin-
mediated stimulation of Akt is not impaired in the skeletal muscle of insulin-resistant subjects.136 
The relationship between insulin action and Akt activity, and subsequent downstream events, 
therefore appears to be complex and is incompletely understood. It is likely that the deregulation 
of additional pathways is required for ET-induced impairment in skeletal muscle glucose 
uptake. We hypothesized that the acute ET-1-mediated increase in glucose uptake observed 
in cultured skeletal muscle was due to a transient stress response, since ET-1 alone did not 
increase Akt phosphorylation and is thus unlikely to utilize an insulin-like signaling cascade. 
However, the exposure of skeletal muscle cells to ET-1 did not increase the phosphorylation 
of AMPK and the molecular signal mediating the increased glucose uptake remains to be 
determined. The acute exposure of skeletal muscle cells to ET-1 induced a transient increase 
in the phosphorylation of ERK MAP kinase, which is associated with cell proliferation and 
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migration, as well as the excessive formation of reactive oxygen species.137 ET-1 exposure 
did not alter GLUT1 and GLUT4 gene expression in cultured human muscle cells. Our data 
from Studies III and IV therefore suggest that ET-1-mediated effects on glucose transport in 
cultured human muscle cells may be dependent on signaling downstream of IRS1 Ser636 but 
not dependent on Akt, ERK or AMPK. 
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CONCLUSIONS
ET-1 impairs basal vascular tone and endothelium-dependent vasodilatation in subjects 1. 
with insulin resistance. Dual ETA/ETB but not selective ETA receptor blockade improves 
endothelial function and increases basal blood flow in this group.
ET-1 is involved in the regulation of total body and skeletal muscle glucose uptake in 2. 
subjects with insulin resistance and this negative effect is antagonized by dual ETA/ETB, 
but not selective ETA, receptor blockade.
Prolonged exposure to ET-1 reduces glucose uptake in insulin resistant subjects as well 3. 
as in cultured human skeletal muscle cells. Dual ETA/ETB receptor antagonism improves 
skeletal muscle glucose uptake.
ET-1 reduces glucose uptake via a receptor-dependent pathway which seems to be 4. 
dependent on signalling downstream of IRS1.
Collectively, the obtained data suggest that ET-1 is of pathophysiological importance for 
the development of endothelial dysfunction and contributes to glucometabolic perturbations 
in subjects with insulin resistance. Dual ETA/ETB receptor blockade may be a potential 
therapeutic target in order to improve endothelial function and insulin sensitivity in this 
patient group.
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